NurExone advances ExoPTEN optic nerve injury program to planned rabbit study after rat data shows improved retinal response

• NurExone reported new preclinical optic nerve injury results supporting advancement of its ExoPTEN program into larger-animal studies.
• Findings have already been generated and disclosed; no future presentation date was provided.
• Treated eyes showed preserved or restored retinal activity versus weaker responses in controls, indicating potential functional protection following injury.
• ExoPTEN delivered a statistically significant improvement versus control, reinforcing its status as the lead regenerative candidate.
• Next step is a planned rabbit study to inform delivery, dosing, tolerability, and safety ahead of potential human clinical evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610091603PRIMZONEFULLFEED9843215) on October 09, 2026, and is solely responsible for the information contained therein.